bioAffinity Technologies Launches Large-Scale Study for Noninvasive Lung Cancer Diagnostic

Event summary

  • bioAffinity Technologies initiates a 2,000-patient longitudinal study for its CyPath® Lung diagnostic test.
  • The study will evaluate the test's performance in detecting early-stage lung cancer in high-risk individuals with lung nodules.
  • Up to 20 clinical study sites, including VA medical centers and military hospitals, will participate in the trial.
  • The study is expected to take up to 18 months for patient enrollment and up to 24 months for follow-up.

The big picture

The initiation of this large-scale study is a critical step for bioAffinity Technologies in establishing CyPath® Lung as a standard of care for early lung cancer detection. The test's noninvasive nature and high accuracy could fill a significant diagnostic gap, particularly as lung cancer screening becomes more widespread. The involvement of federal facilities ensures diverse patient data, which could bolster the test's credibility and adoption.

What we're watching

Clinical Validation
Whether the study will confirm CyPath® Lung's high sensitivity and specificity in a larger, more diverse patient population.
Regulatory Pathway
The pace at which bioAffinity Technologies can secure regulatory approvals based on the study results.
Market Adoption
How quickly physicians and healthcare systems will integrate CyPath® Lung into standard care for lung cancer screening.

Related topics

Biotechnology